We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+15.75%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.54B
AUM Growth
+$40.4M
Cap. Flow
-$337M
Cap. Flow %
-21.88%
Top 10 Hldgs %
46.87%
Holding
259
New
90
Increased
52
Reduced
41
Closed
65

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$25.6M
2
TMP icon
Tompkins Financial
TMP
+$13.1M
3
AGEN
Agenus
AGEN
+$6.13M
4
MNKD icon
MannKind Corp
MNKD
+$5.33M
5
MDVN
MEDIVATION, INC.
MDVN
+$3.71M

Top Sells

Rank Stock Value
1
AEGR
Aegerion Pharmaceuticals
AEGR
+$28.4M
2
ABBV icon
AbbVie
ABBV
+$14.7M
3
ZTS icon
Zoetis
ZTS
+$14.2M
4
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$11.5M
5
ARWR icon
Arrowhead Research
ARWR
+$8.75M

Sector Composition

Rank Sector Weight
1 Healthcare 10.49%
2 Financials 0.07%
3 Technology 0.07%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
26
CALL
Celldex Therapeutics
CLDX
$2.79B
$16.2M 1.06%
+305
New +$105K
GILD icon
27
CALL
Gilead Sciences
GILD
$167B
$15.7M 1.02%
2,500
-206
-8% -$12.3K
RPRX
28
PUT
DELISTED
Repros Therapeutics Inc.
RPRX
$15.4M 1%
5,732
+3,388
+145% +$72.6K
CBST
29
CALL
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$14M 0.91%
2,198
+921
+72% +$55.7K
WCG
30
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
$13M 0.84%
1,861
+56
+3% +$3.58K
ALXN
31
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$13M 0.84%
1,116
+727
+187% +$79.8K
SRPT icon
32
CALL
Sarepta Therapeutics
SRPT
$1.63B
$12.8M 0.83%
2,709
+450
+20% +$17.3K
CELG
33
CALL
DELISTED
Celgene Corp
CELG
$12.4M 0.81%
1,614
-7,930
-83% -$556K
EW icon
34
CALL
Edwards Lifesciences
EW
$48.2B
$11.8M 0.77%
10,188
– –
ACAD icon
35
Acadia Pharmaceuticals
ACAD
$4.45B
$11.7M 0.76%
426,600
-377,655
-47% -$7.89M
BAX icon
36
CALL
Baxter International
BAX
$12.6B
$10.9M 0.71%
3,067
-1,427
-32% -$55.4K
ARNA
37
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$10.8M 0.7%
2,056
+1,035
+101% +$69.5K
AZN icon
38
PUT
AstraZeneca
AZN
$267B
$10.7M 0.7%
+2,060
New +$103K
GILD icon
39
Gilead Sciences
GILD
$167B
$9.73M 0.63%
154,871
-19,237
-11% -$1.15M
MNKD icon
40
PUT
MannKind Corp
MNKD
$1.21B
$9.04M 0.59%
3,173
+1,381
+77% +$45.7K
LUMO
41
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$9.03M 0.59%
534
+93
+21% +$15K
CYBX
42
PUT
DELISTED
CYBERONICS INC
CYBX
$8.59M 0.56%
1,693
-4,256
-72% -$223K
AMRN
43
CALL
Amarin Corp
AMRN
$293M
$7.3M 0.47%
578
+152
+36% +$18.2K
ACHN
44
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$7.29M 0.47%
24,139
+16,659
+223% +$114K
ANTH
45
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$7.05M 0.46%
219,325
-19,098
-8% -$592K
MDVN
46
CALL
DELISTED
MEDIVATION, INC.
MDVN
$6.86M 0.45%
2,290
+780
+52% +$22.3K
MDVN
47
DELISTED
MEDIVATION, INC.
MDVN
$6.76M 0.44%
225,698
+129,898
+136% +$3.71M
ITMN
48
CALL
DELISTED
INTERMUNE INC
ITMN
$6.4M 0.42%
4,164
+920
+28% +$12.9K
PCYC
49
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$6.23M 0.4%
+450
New +$49.9K
OPK icon
50
PUT
Opko Health
OPK
$1.23B
$6.03M 0.39%
6,841
+2,600
+61% +$20.9K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2013 Portfolio in Review

As of Q3 2013, Sabby Management held 259 positions worth $1.54B, up 2.7% from $1.5B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sabby Management withdrew a net $337M in Q3 2013, closing 65 positions and reducing 41 holdings. Its most notable exit was AbbVie, an estimated $14.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 11% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Tompkins Financial worth $1.02M.

  • Sabby Management's largest Q3 2013 buy was Tompkins Financial: 288,454 shares worth $1.02M.
  • Sabby Management added most to Vertex Pharmaceuticals in Q3 2013, an estimated $25.6M increase.
  • Sabby Management's biggest Q3 2013 reduction was Aegerion Pharmaceuticals, cutting an estimated $28.4M.
  • Sabby Management fully exited AbbVie in Q3 2013, selling an estimated $14.7M.
  • Sabby Management's ten largest holdings make up 47% of its $1.54B portfolio in Q3 2013.
  • Sabby Management opened 90 new positions and closed 65 in Q3 2013.
  • Sabby Management's portfolio value rose 2.7% quarter-over-quarter to $1.54B.

Based on Sabby Management's 13F filing for Q3 2013, filed 14 Nov 2013.